Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

Researchers discover why people with sickle cell disease get milder cases of malaria

Researchers at Duke University Medical Center may finally have discovered why people with sickle cell disease get milder cases of malaria than individuals who have normal red blood cells.

16 Aug 2012

bluebird bio completes $60 million Series D financing

bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, today announced the successful completion of a $60 million Series D financing. In this round, new investors Deerfield Partners, RA Capital, Ramius Capital Group, and two undisclosed blue chip public investment funds joined existing investors ARCH Venture Partners, Third Rock Ventures, TVM Capital, and Forbion Capital Partners. In addition, Shire plc joined the round as a strategic investor.

25 Jul 2012

Emmaus receives EC Orphan Medicinal Product designation for Levoglutamide

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company's investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease.

18 Jul 2012

Treating Sickle Cell Disease with L-Glutamine

By focusing on how best to help patients, researchers can sometimes find solutions that are much simpler than anticipated. That has been the guiding approach to our efforts to develop a treatment for sickle cell disease.

3 Jul 2012

Midwest patient receives successful stem cell transplant to cure sickle cell disease

Chicagoan Ieshea Thomas is the first Midwest patient to receive a successful stem cell transplant to cure her sickle cell disease without chemotherapy in preparation for the transplant.

19 Jun 2012

Third Rock Ventures announces formation of Global Blood Therapeutics

Third Rock Ventures, LLC today announced the formation of Global Blood Therapeutics, Inc. and its $40.7 million Series A financing of the company.

15 Jun 2012

Ischemic stroke on the rise among N.J. children

Stroke is one of the top 10 causes of death among children according to the National Stroke Association. A new study published today shows that in New Jersey, the diagnosis of ischemic stroke in children, resulting from a loss or obstruction of blood to the brain, is on the rise.

13 Jun 2012

Researchers shed light on key biological events that may lead to new disease treatments

In exploring how proteins interact with crucial DNA sequences to regulate gene activity, researchers have shed light on key biological events that may eventually be manipulated to provide new disease treatments.

8 Jun 2012

New treatment for sickle cell disease developed by Emmaus Medical receives positive opinion from EMA

Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.

30 May 2012

ADVENTRX first quarter net loss increases to $4.2M

ADVENTRX Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2012.

7 May 2012

Human iPS cells accrue genetic changes at about the same rate as replicating cells

A team of researchers from Johns Hopkins University and the National Human Genome Research Institute has evaluated the whole genomic sequence of stem cells derived from human bone marrow cells—so-called induced pluripotent stem (iPS) cells—and found that relatively few genetic changes occur during stem cell conversion by an improved method.

30 Apr 2012

Bullying, ostracism strong predictors of increased symptoms of depression or anxiety

The challenges that come with battling a chronic medical condition or developmental disability are enough to get a young person down. But being left out, ignored or bullied by their peers is the main reason youths with special health care needs report symptoms of anxiety or depression, according to a study to be presented Sunday, April 29, at the Pediatric Academic Societies (PAS) annual meeting in Boston.

30 Apr 2012

UAB researcher wins HudsonAlpha Prize for work on sickle cell and related blood disorders

Tim Townes, Ph.D., University of Alabama at Birmingham, was awarded the HudsonAlpha Prize for his work on sickle cell and related blood disorders. The $20,000 monetary award acknowledges exceptional talent, dedication and discovery by Alabama's best and brightest researchers.

30 Apr 2012

Physical activity reduces oxidative stress in people with SCT

Sickle cell disease (SCD), an inherited condition that causes red blood cells to sometimes deform into a crescent shape, affects an estimated 100,000 Americans, typically those of African descent. However, far more have sickle cell trait (SCT), caused when individuals carry just a single copy of the disease-causing mutation in their genes.

26 Apr 2012

ASH report urges federal agencies to invest in 7 distinct areas of research

The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.

25 Apr 2012

Shire enters agreement to acquire FerroKin BioSciences

Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.

15 Mar 2012

HemaQuest closes $13 million extension of Series B financing

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has closed a $13 million extension of their Series B financing.

12 Mar 2012

National Library of Medicine acquires papers of sickle cell disease expert

The National Library of Medicine of the National Institutes of Health (NIH), the world's largest medical library, announced recently the acquisition of the papers of Charles F. Whitten, M.D., distinguished professor of pediatrics and associate dean of medicine emeritus at Wayne State University. Whitten passed away in 2008.

14 Feb 2012

Tennessee Gov. declares February as 'St. Jude Month'

In 1962, St. Jude Children's Research Hospital opened its doors amid an emotionally charged debate regarding how to treat childhood cancer. At that time, few children with the most common form of childhood cancer survived, and many physicians believed treatment was futile. St. Jude physicians and researchers took a radically different approach, and these efforts proved pivotal in changing the way the world treats childhood cancer.

6 Feb 2012

Pediatric research project to expand data collection linked to newborn screening results

Within the first days of life, screening tests are performed on all newborns born in the U.S. to identify rare and often life-threatening medical conditions that are not apparent at birth. These newborn screening programs have been operating for decades, permitting doctors to intervene early and improve outcomes in potentially devastating conditions.

18 Jan 2012

Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

Researchers discover why people with sickle cell disease get milder cases of malaria

bluebird bio completes $60 million Series D financing

Emmaus receives EC Orphan Medicinal Product designation for Levoglutamide

Treating Sickle Cell Disease with L-Glutamine

Midwest patient receives successful stem cell transplant to cure sickle cell disease

Third Rock Ventures announces formation of Global Blood Therapeutics

Ischemic stroke on the rise among N.J. children

Researchers shed light on key biological events that may lead to new disease treatments

New treatment for sickle cell disease developed by Emmaus Medical receives positive opinion from EMA

ADVENTRX first quarter net loss increases to $4.2M

Human iPS cells accrue genetic changes at about the same rate as replicating cells

Bullying, ostracism strong predictors of increased symptoms of depression or anxiety

UAB researcher wins HudsonAlpha Prize for work on sickle cell and related blood disorders

Physical activity reduces oxidative stress in people with SCT

ASH report urges federal agencies to invest in 7 distinct areas of research

Shire enters agreement to acquire FerroKin BioSciences

HemaQuest closes $13 million extension of Series B financing

National Library of Medicine acquires papers of sickle cell disease expert

Tennessee Gov. declares February as 'St. Jude Month'

Pediatric research project to expand data collection linked to newborn screening results

Forensics and toxicology - Industry Focus eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

Forensics and toxicology - Industry Focus eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in